2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin Receptor

Related Products

PDF 2.76 MB

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-114564
    Satigrel
    		Inhibitor 99.85%
    Satigrel (E5510) is a potent inhibitor of platelet aggregation. Satigrel inhibits collagen- and arachidonic acid-induced platelet aggregation through preventing thromboxane A2 synthesis by selective inhibition of the target enzyme, PGHS1, which exists in platelets. Satigrel inhibits PGHS1 (IC50: 0.081 μM) and PGHS2 (IC50: 5.9 μM). Satigrel is against Type III PDE, Type V and Type II (IC50: 15.7 μM, 39.8 μM and 62.4 μM, respectively).
    Satigrel
  • HY-153935
    EP4-IN-1
    		Antagonist 99.94%
    EP4-IN-1 is a potent prostanoid EP4 receptor inhibitor. EP4-IN-1 is extracted from patent WO2023025270 (example 1), and exhibits prospect in tumor immunity and anti-inflammatory analgesia research.
    EP4-IN-1
  • HY-101430
    PGD2-IN-1
    		Antagonist 98.24%
    PGD2-IN-1 is an antagonist of DP extracted from patent WO 2006044732 A2, example 15 (d); has an IC50 of 0.3 nM.
    PGD2-IN-1
  • HY-113246
    15-keto-Prostaglandin F2a
    		99.2%
    15-keto-Prostaglandin F2α (15-keto-PGF2α) is a metabolite of Prostaglandin F2α. Prostaglandin F2α. Prostaglandin F2α is an orally active, potent prostaglandin F (PGF) receptor (FP receptor) agonist and plays a key role in the onset and progression of labour.
    15-keto-Prostaglandin F2a
  • HY-113459
    Prostaglandin F1a
    		98.10%
    Prostaglandin F1a is a compound that has the effect of contracting smooth muscle and lowering blood pressure.
    Prostaglandin F1a
  • HY-10414
    MK-2894 sodium salt
    		Antagonist 98.94%
    MK-2894 sodium salt is a potent, selective, orally active and high affinity (Ki=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 nM). MK-2894 sodium salt possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis.
    MK-2894 sodium salt
  • HY-19499
    AMG-009
    		Antagonist 98.08%
    AMG-009 is a potent antagonist of prostaglandin D2, with IC50 of 3 nM and 12 nM for CRTH2 and DP receptors, respectively.
    AMG-009
  • HY-118830
    13,14-Dihydro-15-keto prostaglandin D2
    		Agonist 99.90%
    13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation.
    13,14-Dihydro-15-keto prostaglandin D2
  • HY-106067A
    Dazoxiben hydrochloride
    		Inhibitor 99.72%
    Dazoxiben hydrochloride is a potent and orally active thromboxane (TX) synthase inhibitor.
    Dazoxiben hydrochloride
  • HY-101695
    EP1-antagonist-1
    		Antagonist 98.60%
    EP1-antagonist-1 is a EP1 antagonist with a pKi of 7.54 and an pIC50 of 8.5.
    EP1-antagonist-1
  • HY-115462
    PGN-9856
    		Agonist 98.90%
    PGN-9856 is a selective and high affinity (pKi ≥ 8.3) ligand at EP2 receptor. PGN-9856 is a potetn and non-prostanoid EP2 receptor agonist (pEC50 ≥ 8.5). PGN-9856 shows anti-inflammatory and anti-glaucoma activities.
    PGN-9856
  • HY-109134
    Pizuglanstat
    		Inhibitor 99.70%
    Pizuglanstat (compound 3) is a prostaglandin D synthase inhibitor with an IC50 of 76 nM for human hematopoietic prostaglandin D synthases (H-PGDS). Pizuglanstat can be used for myodegenerative disease research, such as muscular dystrophy.
    Pizuglanstat
  • HY-111539
    BAY-1316957
    		Antagonist 99.73%
    BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC50 of 15.3 nM for human EP4-R. BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for endometriosis research.
    BAY-1316957
  • HY-19923
    Aganepag isopropyl
    		Agonist 98.61%
    Aganepag isopropyl (AGN-210961) is an EP2 agonist.
    Aganepag isopropyl
  • HY-16344
    Nedocromil sodium
    		Inhibitor
    Nedocromil sodium suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
    Nedocromil sodium
  • HY-17477
    Guacetisal
    		Inhibitor 99.95%
    Guacetisal is obtained from the esterification of acetylsalicylic acid with guaiacol which has the potential for chronic bronchitis treatment extracted from patent CN 106866420 A.
    Guacetisal
  • HY-100304A
    KW-8232
    		Inhibitor 98.10%
    KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232
  • HY-13213
    AM211
    		Antagonist 98.79%
    AM211 is a potent, selective and orally bioavailable prostaglandin D2 (PGD2) receptor type 2 (DP2) antagonist, with IC50s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat DP2, respectively.
    AM211
  • HY-B0601
    Tafluprost acid
    		Agonist 99.80%
    Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma.
    Tafluprost acid
  • HY-121018
    Daltroban
    		Antagonist 98.1%
    Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.
    Daltroban
Cat. No. Product Name / Synonyms Application Reactivity
Prostaglandin Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.